Similar articles

• Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites.

  Hiroshima Y, Tajima K, Shiono Y, Suzuki I, Kouno K, Yamamoto M, Kato Y, Kato T. Hiroshima Y, et al. Ann Hematol. 2012 Sep;91(9):1499-500. doi: 10.1007/s00277-012-1410-9. Epub 2012 Jan 28. Ann Hematol. 2012. PMID: 22281990 Free PMC article. No abstract available.
• Hematology: Follicular lymphoma: maintenance therapy is (often) indicated.

  Seymour JF. Seymour JF. Nat Rev Clin Oncol. 2009 Nov;6(11):624-6. doi: 10.1038/nrclinonc.2009.159. Nat Rev Clin Oncol. 2009. PMID: 19861993 No abstract available.
• A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma.

  Marcus R, Aultman R, Jost F. Marcus R, et al. Br J Cancer. 2010 Jan 5;102(1):19-22. doi: 10.1038/sj.bjc.6605443. Epub 2009 Nov 17. Br J Cancer. 2010. PMID: 19920818 Free PMC article.
• Follicular lymphoma: 2012 update on diagnosis and management.

  Freedman A. Freedman A. Am J Hematol. 2012 Oct;87(10):988-95. doi: 10.1002/ajh.23313. Am J Hematol. 2012. PMID: 23001911 Review.
• Rituximab maintenance versus retreatment in follicular lymphoma.

  Palla AR, Hamadani M. Palla AR, et al. Hematol Oncol. 2013 Dec;31(4):171-8. doi: 10.1002/hon.2033. Epub 2012 Oct 9. Hematol Oncol. 2013. PMID: 23044794 Review.